Insulet Corporation, a medical device company, develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The Company offers Omnipod Insulin Management System (Omnipod System), which consists of the OmniPod, an easy-to-use continuous insulin delivery system and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of subcutaneous drugs across various therapeutic areas. Insulet Corporation sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors.
Type | Public | |
Founded | 2000 | |
HQ | Acton, MA, US | Map |
Website | insulet.com | |
Employee Ratings | ||
Overall Culture | C- | More |
USD | |
---|---|
Revenue (Q1, 2022) | 295.4m |
Gross profit (Q1, 2022) | 209.7m |
Net income (Q1, 2022) | 27.8m |
EBIT (Q1, 2022) | 37.9m |
Market capitalization (1-Aug-2022) | 16.9b |
Closing stock price (1-Aug-2022) | 245.7 |
Cash (31-Mar-2022) | 724.9m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 152.3m | 211.4m | 247.1m | 288.7m | 324.2m | 367.0m | 463.8m | 563.8m | 738.2m | 904.4m | 1.1b |
Revenue growth, % | 17% | 12% | 13% | ||||||||
Cost of goods sold | 85.5m | 119.0m | 134.7m | 145.4m | 176.1m | 155.9m | 186.6m | 193.7m | 257.9m | 322.1m | 346.7m |
Gross profit | 66.7m | 92.3m | 112.4m | 143.3m | 148.2m | 211.1m | 277.2m | 370.2m | 480.3m | 582.3m | 752.1m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 32.2m | 44.6m | 47.8m | 51.0m | 54.8m | 57.4m | 60.1m | 61.1m | 69.2m | 72.0m | 75.0m | 61.2m | 75.6m | 87.3m | 81.2m | 87.3m | 94.9m | 101.7m | 109.8m | 121.8m | 123.6m | 124.3m | 151.1m | 159.6m | 177.1m | 192.1m | 1.5m | 226.3m | 500.0k | 252.3m | 263.2m | 275.6m | 295.4m |
Cost of goods sold | 17.7m | 26.0m | 27.5m | 28.7m | 30.4m | 32.2m | 33.3m | 33.7m | 36.4m | 36.2m | 36.9m | 28.4m | 41.2m | 51.7m | 37.2m | 36.9m | 39.2m | 42.3m | 45.1m | 48.2m | 47.8m | 42.2m | 49.1m | 52.9m | 60.7m | 69.0m | 71.1m | 83.8m | 82.2m | 84.8m | 80.5m | 86.9m | 85.7m |
Gross profit | 14.5m | 18.6m | 20.3m | 22.3m | 24.4m | 25.2m | 26.8m | 27.4m | 32.8m | 35.8m | 38.0m | 32.8m | 34.4m | 35.7m | 44.1m | 50.5m | 55.6m | 59.4m | 64.6m | 73.6m | 75.8m | 82.1m | 102.0m | 106.7m | 116.4m | 123.1m | (69.6m) | 142.5m | (81.7m) | 167.5m | 182.7m | 188.7m | 209.7m |
Gross profit Margin, % | 45% | 42% | 43% | 44% | 45% | 44% | 45% | 45% | 47% | 50% | 51% | 54% | 45% | 41% | 54% | 58% | 59% | 58% | 59% | 60% | 61% | 66% | 67% | 67% | 66% | 64% | (4640%) | 63% | (16340%) | 66% |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 94.0m | 57.3m | 149.7m | 151.2m | 122.7m | 137.2m | 272.6m | 113.9m | 213.7m | 907.2m | 806.4m |
Accounts Receivable | 23.2m | 33.3m | 33.1m | 39.9m | 48.4m | 28.8m | 53.4m | 63.3m | 69.3m | 83.8m | |
Prepaid Expenses | 3.7m | 4.5m | 5.9m | 4.0m | 5.7m | 9.9m | 24.3m | 31.1m | |||
Inventories | 11.8m | 14.9m | 9.5m | 13.1m | 14.0m | 35.5m | 33.8m | 71.4m | 154.3m | 303.2m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 106.7m | 103.8m | 83.0m | 70.1m | 63.4m | 148.1m | 150.9m | 153.9m | 145.6m | 175.5m | 146.4m | 145.6m | 145.1m | 145.5m | 111.6m | 75.7m | 215.4m | 76.0m | 73.5m | 102.2m | 203.1m | 136.2m | 126.6m | 129.3m | 119.9m | 419.9m | 201.4m | 779.1m | 838.1m | 820.7m | 854.6m | 856.6m | 724.9m |
Accounts Receivable | 20.4m | 17.3m | 26.2m | 25.6m | 30.1m | 31.1m | 33.7m | 34.5m | 36.7m | 41.8m | 47.1m | 36.1m | 31.8m | 31.8m | 40.5m | 38.7m | 38.5m | 40.6m | 37.8m | 47.2m | 50.4m | 49.7m | 70.0m | 68.7m | 67.0m | 65.1m | 80.1m | 85.4m | 97.9m | 100.3m | 114.3m | 153.5m | |
Prepaid Expenses | 4.8m | 3.7m | 3.5m | 4.3m | 5.6m | 6.4m | 6.6m | 5.9m | 7.1m | 5.7m | 3.4m | 3.7m | 3.4m | 4.0m | 5.7m | 6.8m | 7.9m | 8.2m | 8.4m | 8.0m | 17.4m | 17.6m | 17.9m | 28.0m | 25.2m | 20.7m | 43.9m | 59.6m | 53.4m | 73.6m | 82.7m | 76.5m | 71.7m |
Inventories | 16.0m | 13.1m | 14.7m | 16.4m | 15.1m | 9.2m | 6.0m | 5.4m | 10.4m | 8.8m | 9.7m | 20.1m | 23.4m | 13.0m | 14.0m | 24.5m | 32.7m | 34.3m | 34.0m | 35.1m | 26.3m | 40.8m | 58.1m | 73.8m | 85.1m | 90.2m | 95.7m | 103.7m | 124.9m | 170.1m | 197.8m | 314.8m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (45.8m) | (51.9m) | (45.0m) | (51.5m) | (73.5m) | (28.9m) | (26.8m) | 3.3m | 11.6m | 6.8m | 16.8m |
Depreciation and Amortization | 8.5m | 11.0m | 11.8m | 12.2m | 15.8m | 13.8m | 15.1m | 15.6m | 27.9m | 55.4m | 64.2m |
Inventories | 1.9m | (3.0m) | 5.4m | (3.6m) | (722.0k) | (24.1m) | 1.7m | (38.8m) | (30.2m) | (50.5m) | (154.4m) |
Accounts Payable | 7.1m | (15.6m) |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (29.3m) | (42.8m) | (14.8m) | (29.3m) | (41.7m) | (10.7m) | (21.2m) | (42.5m) | (6.1m) | (35.3m) | (46.1m) | (11.8m) | (27.3m) | (46.2m) | (12.5m) | (16.7m) | (19.8m) | (10.0m) | (17.7m) | (20.0m) | (6.6m) | (8.3m) | (6.6m) | 4.4m | 5.8m | 6.6m | (2.1m) | 12.3m | 23.9m | (12.4m) | 27.8m | ||
Depreciation and Amortization | 2.8m | 5.7m | 2.8m | 5.5m | 8.1m | 2.9m | 5.8m | 8.9m | 3.1m | 6.1m | 9.2m | 3.4m | 7.1m | 11.4m | 3.4m | 6.8m | 10.5m | 3.3m | 6.7m | 10.5m | 3.5m | 7.9m | 11.3m | 5.1m | 11.0m | 18.8m | 9.7m | 18.8m | 29.7m | 12.8m | 3.5m | 42.5m | 15.3m |
Inventories | (2.2m) | 594.0k | (2.9m) | (4.6m) | (3.3m) | 5.7m | 8.9m | 9.5m | (985.0k) | 699.0k | (198.0k) | (7.0m) | (10.3m) | 312.0k | (2.6m) | (13.1m) | (21.3m) | 1.2m | 1.5m | 428.0k | 6.7m | (8.0m) | (25.3m) | (2.7m) | (14.0m) | (20.0m) | 4.8m | (2.8m) | (22.9m) | (17.9m) | (108.1m) | ||
Accounts Payable | 2.2m | 1.9m | (4.4m) | 14.7m |
USD | Q2, 2011 |
---|---|
Financial Leverage | 2.4 x |
FY, 2016 | |
---|---|
Patents Issued | 23 |
Patents Pending | 32 |
Insulet revenue breakdown by business segment: 62.6% from U.S. Omnipod, 19.6% from International Omnipod and 17.8% from Drug Delivery
Insulet has 6k Twitter Followers. The number of followers has increased 3.5% month over month and increased 6.3% quarter over quarter
3.9k
Tweets
104
Following
6k
Followers
99
Tweets last 30 days
2.1
Avg. likes per Tweet
43.4%
Tweets with engagement
C-
63/100
C
65/100
C+
66/100
C-
64/100
When was Insulet founded?
Insulet was founded in 2000.
Who are Insulet key executives?
Insulet's key executives are Shacey Petrovic, Charles Alpuche and Jim Hollingshead.
How many employees does Insulet have?
Insulet has 1,350 employees.
What is Insulet revenue?
Latest Insulet annual revenue is $1.1 b.
What is Insulet revenue per employee?
Latest Insulet revenue per employee is $813.9 k.
Who are Insulet competitors?
Competitors of Insulet include Tandem Diabetes Care, Reapplix and POPS! Diabetes Care.
Where is Insulet headquarters?
Insulet headquarters is located at 100 Nagog Park, Acton.
Where are Insulet offices?
Insulet has offices in Acton, Billerica, Salt Lake City, San Diego and in 2 other locations.
How many offices does Insulet have?
Insulet has 6 offices.
Receive alerts for 300+ data fields across thousands of companies